DK0814835T3 - Fremgangsmåde til forøgelse af immunogenitet, opnået produkt og farmaceutisk præparat - Google Patents

Fremgangsmåde til forøgelse af immunogenitet, opnået produkt og farmaceutisk præparat

Info

Publication number
DK0814835T3
DK0814835T3 DK95929918T DK95929918T DK0814835T3 DK 0814835 T3 DK0814835 T3 DK 0814835T3 DK 95929918 T DK95929918 T DK 95929918T DK 95929918 T DK95929918 T DK 95929918T DK 0814835 T3 DK0814835 T3 DK 0814835T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
product obtained
increasing immunogenicity
product
immunogenicity
Prior art date
Application number
DK95929918T
Other languages
English (en)
Inventor
Eric Batiment A Apparte Prieur
Didier Betbeder
Christian Davrinche
Jean-Luc Davignon
Original Assignee
Ceva Sante Animale
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale, Inst Nat Sante Rech Med filed Critical Ceva Sante Animale
Application granted granted Critical
Publication of DK0814835T3 publication Critical patent/DK0814835T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DK95929918T 1994-08-31 1995-08-31 Fremgangsmåde til forøgelse af immunogenitet, opnået produkt og farmaceutisk præparat DK0814835T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9410479A FR2723849B1 (fr) 1994-08-31 1994-08-31 Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique

Publications (1)

Publication Number Publication Date
DK0814835T3 true DK0814835T3 (da) 2004-03-08

Family

ID=9466603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95929918T DK0814835T3 (da) 1994-08-31 1995-08-31 Fremgangsmåde til forøgelse af immunogenitet, opnået produkt og farmaceutisk præparat

Country Status (12)

Country Link
US (1) US6342226B1 (da)
EP (1) EP0814835B1 (da)
JP (1) JPH10509690A (da)
KR (1) KR970705411A (da)
AT (1) ATE253377T1 (da)
AU (1) AU704633B2 (da)
CA (1) CA2198479A1 (da)
DE (1) DE69532088T2 (da)
DK (1) DK0814835T3 (da)
ES (1) ES2210310T3 (da)
FR (1) FR2723849B1 (da)
WO (1) WO1996006638A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6741664B1 (en) * 1999-02-05 2004-05-25 Broadcom Corporation Low-latency high-speed trellis decoder
CZ20013527A3 (cs) 1999-04-02 2002-10-16 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DK2133100T3 (da) 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
FR2815870A1 (fr) * 2000-10-27 2002-05-03 Biovector Therapeutics Utilisation de particules hydrophiles associees a des antigenes identiques ou differents pour la preparation de compositions de vaccin
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
MXPA05007295A (es) 2003-01-06 2005-09-30 Corixa Corp Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
EP1766096B1 (en) 2004-05-25 2013-01-02 Oregon Health and Science University Hiv vaccination usingand hcmv-based vaccine vectors
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
CN101184504A (zh) 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
CN101273055B (zh) 2005-04-29 2016-03-16 葛兰素史密丝克莱恩生物有限公司 用于预防或治疗结核分枝杆菌感染的新方法
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US7375084B2 (en) 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP1897538A1 (en) * 2006-08-23 2008-03-12 Stallergenes Sa Formulations for antigen-specific tolerance induction
WO2008156829A2 (en) * 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
JP2011507919A (ja) 2007-12-27 2011-03-10 バクスター・インターナショナル・インコーポレイテッド 修飾第ｉｘ因子
EP2262480B1 (en) 2008-03-04 2018-02-14 Liquidia Technologies, Inc. Immunomodulator particles
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
CN107880101B (zh) 2011-11-11 2021-12-21 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CA3091352A1 (en) 2018-02-21 2019-08-29 The University Of Montana Diaryl trehalose compounds and uses thereof
US11572381B2 (en) 2018-03-02 2023-02-07 The University Of Montana Immunogenic trehalose compounds and uses thereof
BR112021023292A2 (pt) 2019-05-23 2022-02-08 The Univ Of Montana Composto, formulação, composição de vacina, composição farmacêutica, e, método para modular uma resposta imune em um indivíduo
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) * 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique

Also Published As

Publication number Publication date
EP0814835A1 (fr) 1998-01-07
DE69532088D1 (de) 2003-12-11
AU3349095A (en) 1996-03-22
AU704633B2 (en) 1999-04-29
KR970705411A (ko) 1997-10-09
US6342226B1 (en) 2002-01-29
DE69532088T2 (de) 2004-09-02
CA2198479A1 (fr) 1996-03-07
ES2210310T3 (es) 2004-07-01
EP0814835B1 (fr) 2003-11-05
WO1996006638A1 (fr) 1996-03-07
FR2723849B1 (fr) 1997-04-11
FR2723849A1 (fr) 1996-03-01
ATE253377T1 (de) 2003-11-15
JPH10509690A (ja) 1998-09-22

Similar Documents

Publication Publication Date Title
DK0814835T3 (da) Fremgangsmåde til forøgelse af immunogenitet, opnået produkt og farmaceutisk præparat
ATE77741T1 (de) Insbesondere zum tragen von biologisch aktiven molekuelen geeignetes teilchenfoermiges vektorsystem und verfahren zu seiner herstellung.
DE69130113T2 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DK13491D0 (da) Anvendelse af et enzymholdigt granulat og fremgangsmaade til fremstilling af et forderstof i tabletform
ID22039A (id) Formulasi oral lepas cepat yang tertunda dan metode pembuatannya
FR2704145B1 (fr) Vecteur particulaire et composition pharmaceutique le contenant.
NO953043L (no) Fremgangsmåte for syntetisere acetotriglyceridfett
EP0926951A4 (en) METHOD FOR TREATING LIVER DISEASES MEDIATED BY MULTIPLE UNSATURATED LIPID METABOLITES AND TESTS FOR EPOXY HYDROLASE INHIBITORS
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
ATE25246T1 (de) Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE69637523D1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
DK32684A (da) Fremgangsmaade til fremstilling af 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol og mellemprodukter til brug herfor
NL7903400A (nl) Werkwijze voor de bereiding van alpha,beta-onverzadigde n-gesubstitueerde carbonzuuramiden.
AU8215791A (en) Method for preparing a lipoprotein modified by the incorporation of a lipophilic active substance
EP0868435A4 (en) HIGHLY EFFICIENT TISSUE-SPECIFIC SYSTEM FOR PROVIDING CONNECTIONS USING A STREPTAVIDINE PROTEIN A FUSION PROTEIN
ATE489T1 (de) Sila-substituierte 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung, arzneimittel und verfahren zu deren herstellung.
JPS57109797A (en) Preparation of low-molecular weight keratinous substance
DE3773077D1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
LV10617A (lv) 3-aizvietoti 1,2,3,4-oksatriazol-5-imina savienojumi to iegusanas metode un tos satuross farmaceitisks preparats
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
FR2731355B1 (fr) Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
ATE232392T1 (de) Pharmazeutische zusammensetzung, enthaltend komplementproteine, zur behandlung von helicobacter-infektionensowie ein verfahren zur herstellung der zusammensetzung
JPS51136648A (en) Process for preparation of 2-(1-alkenyl)-2-cyclopentenone
ATE328088T1 (de) Transketolase-verwandtes protein